Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,168 across all filing types
Latest filing 2026-06-08 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 96% confidence The document is an official announcement by Chongqing Boteng Pharmaceutical Technology Co., Ltd. detailing the top ten shareholders and top ten unrestricted shareholders ahead of a share repurchase (“回购股份事项”). It references board resolutions on a share buyback plan and regulatory guidelines for share repurchases. This clearly falls under “Transaction in Own Shares” (company buying back its own shares).
2026-06-08 Chinese
回购报告书
Transaction in Own Shares Classification · 91% confidence The document is a detailed “回购报告书” (share repurchase report) issued by the company and its board describing the purpose, conditions, method, scale, price, timeline, regulatory compliance and risk factors of a share buyback. It is neither a mere announcement of publication nor a broader financial report; it specifically addresses the company’s repurchase of its own shares. Under the taxonomy, this corresponds to Transaction in Own Shares (POS).
2026-06-08 Chinese
关于以集中竞价交易方式回购公司股份用于注销并减少注册资本方案的公告
Transaction in Own Shares Classification · 95% confidence The document is a formal company announcement detailing a share repurchase (open-market buyback) plan: it specifies the number of A‐shares to be repurchased, price range, funding source, timeline, purpose (cancellation and reduction of registered capital), board approvals, risk factors, and related authorizations. This clearly falls under the category of a transaction in own shares (share repurchase) rather than an earnings release, annual report, or financing update. Therefore, it should be classified as POS.
2026-06-05 Chinese
关于对外投资进展暨终止建设斯洛文尼亚研发生产基地的公告
Regulatory Filings Classification · 82% confidence The document is a corporate exchange announcement by Chongqing Porton Pharmaceutical Technology Co., Ltd. detailing the progress and termination of its Slovenia R&D production base investment project. It does not contain financial statements, earnings highlights, share issuance details, board or management changes, proxy materials, or fundraising activities. It is a general regulatory announcement about a project termination and risk disclosure, so it falls into the fallback “Regulatory Filings (RNS)” category.
2026-06-05 Chinese
第六届董事会第十次临时会议决议公告
Transaction in Own Shares Classification · 92% confidence The document is a notice of the board of directors’ resolution approving a concentrated auction share buyback plan, detailing the purpose, conditions, price range, funds, authorization and implementation period of the company’s share repurchase. This is a direct announcement of a transaction in the company’s own shares. Therefore, it falls under the “Transaction in Own Shares” category (POS).
2026-06-05 Chinese
关于对外投资进展暨澄清公告
Legal Proceedings Report Classification · 82% confidence The document is a corporate clarification announcement (“公告”) concerning the company’s external investment progress and related legal risk with Novartis’s Slovenian affiliate. It is not a financial report or earnings release but an update on potential legal claims, negotiations, and risk mitigation steps. This fits the “Legal Proceedings Report” category (LTR).
2026-05-19 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.